Forte Biosciences Inc
FBRX
查看详细走势图
28.200USD
-1.130-3.85%
交易中 （美东）报价延迟15分钟
353.17M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.85%
5天
+28.42%
1月
+53.14%
6月
+92.36%
今年开始到现在
+24.17%
1年
+45.81%
查看详细走势图
TradingKey Forte Biosciences Inc股票评分
单位: USD 更新时间: 2025-12-22操作建议
Forte Biosciences Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名86/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价54.80。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Forte Biosciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
买入
评级
54.800
目标均价
+177.61%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Forte Biosciences Inc亮点
亮点风险
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Forte Biosciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Forte Biosciences Inc简介
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
公司代码FBRX
公司Forte Biosciences Inc
CEOWagner (Paul A)
网址https://www.fortebiorx.com/home/default.aspx
常见问题
Forte Biosciences Inc(FBRX)的当前股价是多少？
Forte Biosciences Inc(FBRX)的当前股价是 28.200。
Forte Biosciences Inc的股票代码是什么？
Forte Biosciences Inc的股票代码是FBRX。
Forte Biosciences Inc股票的52周最高点是多少？
Forte Biosciences Inc股票的52周最高点是29.710。
Forte Biosciences Inc股票的52周最低点是多少？
Forte Biosciences Inc股票的52周最低点是4.900。
Forte Biosciences Inc的市值是多少？
Forte Biosciences Inc的市值是353.17M。
Forte Biosciences Inc的净利润是多少？
Forte Biosciences Inc的净利润为-35.48M。
现在Forte Biosciences Inc(FBRX)的股票是买入、持有还是卖出？
根据分析师评级，Forte Biosciences Inc(FBRX)的总体评级为买入，目标价格为54.800。
Forte Biosciences Inc(FBRX)股票的每股收益（EPS TTM）是多少
Forte Biosciences Inc(FBRX)股票的每股收益（EPS TTM）是-0.081。
相关品种
